Sign in to view content

Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema

John W. Kitchens, MD

Video
Published 2022

Related

Outcomes of Eyes Lost to Follow-up After Treatment With Intraocular and Periocular Steroid Injections
John W Hinkle, MD
On Demand Cases, Courses, and Papers
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more